Peptides Weight LossMetabolic
Survodutide
Survodu · BI 456906
Investigational dual GLP-1/glucagon receptor agonist for obesity and MASH; weekly injection.
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 6 days
- Bioavailability
- 80%
- Typical dose
- 0.72–9.6 mg